"Disulfiram" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
| Descriptor ID |
D004221
|
| MeSH Number(s) |
D02.241.081.251.869.220.250 D02.886.520.150.175 D02.886.706.200.200
|
| Concept/Terms |
Disulfiram- Disulfiram
- Bis(diethylthiocarbamoyl) Disulfide
- Tetraethylthioperoxydicarbonic Diamide, ((H2N)C(S))2S2
- Tetraethylthiuram Disulfide
- Disulfide, Tetraethylthiuram
|
Below are MeSH descriptors whose meaning is more general than "Disulfiram".
Below are MeSH descriptors whose meaning is more specific than "Disulfiram".
This graph shows the total number of publications written about "Disulfiram" by people in this website by year, and whether "Disulfiram" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disulfiram" by people in Profiles.
-
Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents. Prog Neuropsychopharmacol Biol Psychiatry. 2022 04 20; 115:110506.
-
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatr Genet. 2021 06 01; 31(3):88-94.
-
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict. 2019 07; 28(4):311-317.
-
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. J Exp Clin Cancer Res. 2017 02 01; 36(1):22.
-
Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol. 2015 Jun; 9(6):1155-68.
-
Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV. AIDS Res Hum Retroviruses. 2015 Jan; 31(1):137-41.
-
Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014 Oct 15; 74(20):5819-31.
-
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend. 2014 Mar 01; 136:36-42.
-
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1A-adrenoceptor gene variation. Eur Neuropsychopharmacol. 2013 Nov; 23(11):1401-7.
-
ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013 Jul; 23(7):333-40.